Amgen Reports First Quarter 2018 Financial Results

THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include:

Total revenues increased 2 percent versus the first quarter of 2017 to $5.6 billion.

Product sales grew 3 percent globally. All new and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab) showed double-digit growth.

GAAP earnings per share (EPS) increased 16 percent to $3.25 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding.

GAAP operating income increased 5 percent to $2.7 billion and ...

Source: Amgen News Release - April 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news